Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Investorideas.com newswire, biotech stocks and industry

Friday, July 8, 2016

#InvestorIdeas Adds #Technology and #Biotech #Stocks ($INSY, $CTBO and $EBIO) to Directories

#InvestorIdeas Adds #Technology and #Biotech #Stocks ($INSY, $CTBO and $EBIO) to Directories

Technology Stock Additions Include: TSX Venture: $AKR.V, $BPL.V, $MKT.V, $EQ.V, $FSW.V, $KBY.V, $AT.V, $BKD.V, $BTL.V, $DXX.V, $MVP.V, $MBO.V, $MV.V, $PGV.V, $PFM.V


Point Roberts, WA, Delta BC – July 8, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories.  Additions are mainly within the technology sector, with a focus on TSX Venture Exchange Traded Stocks.

Also added are three biotech companies -  INSYS Therapeutics, Inc. (NasdaqGM: INSY) focused on novel drug delivery systems and treating addiction to opioids, opioid overdose and epilepsy; Cantabio Pharmaceuticals Inc. (OTC:CTBO)  which is focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s, Parkinson’s and oxidative stress; and Eleven Biotherapeutics, Inc. (NasdaqGM:EBIO) which focuses on the discovery and development of protein therapeutics to treat diseases of the eye.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.


Tech Companies Added: Ackroo Inc. (TSX:AKR.V), Bluedrop Performance Learning Inc (TSX:BPL.V), DeepMarkit Corp. (TSX:MKT.V), EQ Inc. (TSX:EQ.V), Fireswirl Technologies Inc (TSX:FSW.V), Kona Bay Technologies Inc. (TSX:KBY.V), AcuityAds Holdings Inc (TSX: AT.V), Breaking Data Corp. (TSX:BKD.V), BTL Group Ltd (TSX:BTL.V), DXStorm.com Inc (TSX:DXX.V), MediaValet Inc (TSX:MVP.V), Mobio Technologies Inc. (TSX:MBO.V), MOVIT Media Corp. (TSX:MV.V), Prodigy Ventures Inc (TSX:PGV.V) and ProntoForms Corporation (TSX:PFM.V).

Biotech:
INSYS Therapeutics, Inc. (NasdaqGM: INSY) is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product, Subsys® (fentanyl sublingual spray) but has received approval for the marketing of Syndros (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy and other disease areas with high unmet need. Subsys® and Syndros are trademarks of Insys Therapeutics, Inc.

Cantabio Pharmaceuticals Inc. (OTC:CTBO) is focused on bringing novel, first in class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s and Parkinson’s, and oxidative stress.

Eleven Biotherapeutics, Inc. (NasdaqGM:EBIO) is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411



No comments:

Post a Comment